Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 101Neoplasms, Plasma Cell 12Recurrence 9Lymphoma 8Immunoglobulin Light-chain Amyloidosis 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Acute 5Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 3Paraproteinemias 3Hematologic Neoplasms 3Amyloidosis 3Renal Insufficiency 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Burkitt Lymphoma 2beta-Thalassemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thalassemia 1Sarcoma, Myeloid 1Prostatic Neoplasms 1Plasmacytoma 1Plasmablastic Lymphoma 1Peripheral Nervous System Diseases 1

Interventions

Cyclophosphamide 8Rituximab 5fludarabine 4Vincristine 4Prednisone 4Doxorubicin 4fludarabine phosphate 3Tacrolimus 3Mycophenolic Acid 3Etoposide 3Busulfan 3venetoclax 2entrectinib 2atezolizumab 2alectinib 2acalabrutinib 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Bortezomib 2trametinib 1pertuzumab 1pembrolizumab 1obinutuzumab 1liposomal doxorubicin 1isatuximab 1ibrutinib 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Bortezomib × 1 year × Clear all
NCT00092222 2026-06-05

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡